 |
delta-1,4,9(11)-pregnatriene-17-alpha,21-dihydroxy-16-alpha-methyl-3,20-dione |
|---|---|
| Trade Name | |
| Orphan Indication | Duchenne muscular dystrophy |
| USA Market Approval | USA |
| USA Designation Date | 2011-12-02 00:00:00 |
| Sponsor | ReveraGen Biopharma;9700 Great Seneca Highway;Rockville, MD, 20850 |
